A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Inclusion Criteria: * Patient is a non-smoking male or female ≤ 17 years of age on the day of signing the informed consent. Infants must be at least 1 month of age * A diagnosis of primary or secondary pediatric glaucoma or ocular hypertension in one or both eyes * A history of IOP greater than or equal to 22 mmHg in at least one eye. Newly diagnosed patients may have this criterion fulfilled at the pre-study visit. * Patient is currently prescribed ocular hypotensive medication and who according to investigator's judgement may discontinue the use at least day before the Day 1 visit, or patient is treatment-naïve (those who have never used used ocular hypotensive medication). * Female patients of reproductive potential must demonstrate a negative pregnancy test at the pre-study visit * Patient is judged to be in good health, other than having glaucoma or ocular hypertension, based on medical history, physical examination, vital signs measurements, and laboratory safety tests performed at the pre-study visit and/or prior to administration of the initial dose of study drug * Patient has no clinically significant abnormality on electrocardiogram (ECG) performed at the pre-study visit * Parent/legal guardian and/or patient have/has provided a written informed consent (according to existing local regulations) and patient assent has been given as applicable. * The patient and parent/guardian should agree to comply with study restrictions, treatment plan, procedures and keep schedu…